- Jul 30, 2021
International Collaboration Helps Refine Treatment for Childhood Leukemia
Scientists at St. Jude Children’s Research Hospital are working with colleagues in China to develop better therapy for childhood acute lymphoblastic leukemia (ALL). Results from a large phase 3 noninferiority clinical trial definitively showed that vincristine and dexamethasone pulses can be eliminated in patients with low-risk disease. Read more: https://www.newswise.com/articles/international-collaboration-helps-refine-treatment-for-childhood-leukemia
- Jul 29, 2021
Tiny bubbles used to treat common childhood cancer
Researchers at UCL have developed a new way to deliver drugs that can shut down cancer-promoting mutations in neuroblastoma. The findings in mice, show the method, which uses tiny bubbles to deliver therapies directly to tumor cells, reduced tumor growth and improved survival. Read more: https://medicalxpress.com/news/2021-07-tiny-common-childhood-cancer.html
- Jul 26, 2021
Geneticists Reveal How Mutation Causes a Devastating Childhood Cancer
Geneticists from Trinity College Dublin have discovered how a specific genetic mutation called H3K27M causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and — in lab studies working with model cell types — successfully reverse its effects to slow cancer cell growth with a targeted drug. Read more: https://scitechdaily.com/geneticists-reveal-how-mutation-causes-a-devastating-childhood-cancer-use-drug-to-reverse-its-effects/
- Jul 21, 2021
Frailty contributes to neurocognitive decline in young adult childhood cancer survivors
Scientists at St. Jude Children's Research Hospital have found a link between post-cancer treatment frailty and neurocognitive decline in young adult childhood cancer survivors. Read more: https://www.news-medical.net/news/20210720/Frailty-contributes-to-neurocognitive-decline-in-young-adult-childhood-cancer-survivors.aspx
- Jul 13, 2021
Immunotherapy Trial May Be Feasible to Combat Pediatric Pediatric Brain and Spinal Cord Tumors
An innovative clinical trial led by Dr. Nicholas Vitanza, a neuro-oncologist at Seattle Children’s, shows promise that delivering cancer-fighting chimeric antigen receptor (CAR) T cells directly to the brain for children and young adults with recurrent or refractory brain and central nervous system (CNS) tumors may be feasible and tolerable. Read more: https://pulse.seattlechildrens.org/research-shows-seattle-childrens-pioneering-immunotherapy-trial-may-be-feasible-to-co
- Jul 12, 2021
Can leukemia in children with Down syndrome be prevented?
For the first time, Princess Margaret researchers have mapped out where and how leukemia begins and develops in infants with Down syndrome in preclinical models, paving the way to potentially prevent this cancer in the future. Read more: https://www.eurekalert.org/pub_releases/2021-07/uhn-cli070721.php
- Jul 9, 2021
New generation anti-cancer drug shows promise for children with brain tumours
A genetic map of an aggressive childhood brain tumour called medulloblastoma has helped researchers identify a new generation anti-cancer drug that can be repurposed as an effective treatment for the disease. Read more: https://www.uq.edu.au/news/article/2021/07/new-generation-anti-cancer-drug-shows-promise-children-brain-tumours
- Jul 8, 2021
Potential Treatment May Prevent Cancer Cells From Hijacking Metabolic Pathways
Now researchers in the Feng lab at Boston University School of Medicine (BUSM), in collaboration with scientists in the Simon lab at the Perelman School of Medicine at the University of Pennsylvania (Penn), have not only discovered why this cancer is so aggressive but also reveal a promising therapeutic approach to treat these patients. Read more: https://scitechdaily.com/potential-treatment-may-prevent-cancer-cells-from-hijacking-metabolic-pathways/
- Jul 7, 2021
Melanoma registry results shine light on rare pediatric cancer
Pediatric melanoma is a rare disease with only around 400 cases diagnosed in the United States every year. To better understand this disease and how best to treat it, St. Jude Children's Research Hospital scientists created a registry called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL). Read more: https://www.eurekalert.org/pub_releases/2021-07/sjcr-mrr070621.php
- Jul 6, 2021
Cancer neuroscientists identify a key culprit behind pediatric brain cancer’s spread
Now, research led by USC investigators has shined new light on how medulloblastoma travels to other sites within the central nervous system. The study, which appeared in the journal Cell Reports, showed that an enzyme called GABA transaminase, abbreviated as ABAT, aids metastases in surviving the hostile environment around the brain and spinal cord and in resisting treatment. These findings may provide clues to new strategies for targeting deadly medulloblastoma metasta